On July 29, a report letter about suspected commercial bribery by Colombotai and related personnel was circulated in the market. According to the report letter, the product involved is Lucansastuzumab from Collenbotai. The original price of the drug was 9399 yuan per bottle in 2025. The hospitals involved include Beijing 301 Hospital and 307 Hospital. Commercial bribery and profit delivery methods include issuing cash rebates of 900 to 2,000 yuan for each drug; sending labor costs exceeding 8 million yuan to clinical directors under the guise of targeted sponsorship in the name of the foundation; inflated payment of conference labor fees; and gifting valuable gifts. In response to this, Collumbotai said in response to interface news that the content of the report letter is untrue, and the company will further verify the whistleblower and pursue his legal responsibility.

On July 29, a report letter about suspected commercial bribery by Colombotai and related personnel was circulated in the market. According to the report letter, the product involved is Lucansastuzumab from Collenbotai. The original price of the drug was 9399 yuan per bottle in 2025. The hospitals involved include Beijing 301 Hospital and 307 Hospital. Commercial bribery and profit delivery methods include issuing cash rebates of 900 to 2,000 yuan for each drug; sending labor costs exceeding 8 million yuan to clinical directors under the guise of targeted sponsorship in the name of the foundation; inflated payment of conference labor fees; and gifting valuable gifts. In response to this, Collumbotai said in response to interface news that the content of the report letter is untrue, and the company will further verify the whistleblower and pursue his legal responsibility.